KRAS and lung carcinoma: The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination 1 (BATTLE1) study depicted sorafenib as a successful drug in patients with KRAS mutated tumors [20], an effect that was largely attributed to RAF inhibition.